Stifel Nicolaus lowered shares of CTI BioPharma (NASDAQ:CTIC – Get Rating) from a buy rating to a hold rating in a research note released on Monday morning, The Fly reports.
Other equities analysts have also issued reports about the company. Needham & Company LLC lowered CTI BioPharma from a buy rating to a hold rating in a research report on Wednesday, May 10th. Lake Street Capital lowered CTI BioPharma from a buy rating to a hold rating in a research report on Wednesday, May 10th. StockNews.com raised CTI BioPharma from a sell rating to a hold rating in a research report on Tuesday, March 14th. JMP Securities lowered CTI BioPharma from an outperform rating to a market perform rating in a research report on Thursday, May 11th. Finally, TD Cowen reduced their price objective on CTI BioPharma from $10.00 to $8.00 and set an outperform rating for the company in a research note on Monday, April 17th. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average target price of $10.29.
CTI BioPharma Stock Down 0.3 %
Shares of NASDAQ:CTIC opened at $8.93 on Monday. CTI BioPharma has a twelve month low of $4.01 and a twelve month high of $8.96. The stock’s 50 day moving average is $4.92 and its 200-day moving average is $5.35. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -10.51 and a beta of 0.86.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE grew its stake in shares of CTI BioPharma by 354.5% during the 1st quarter. Bank of America Corp DE now owns 5,900 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 4,602 shares during the period. Shell Asset Management Co. bought a new position in CTI BioPharma in the 4th quarter worth about $47,000. Legal & General Group Plc bought a new position in CTI BioPharma in the 2nd quarter worth about $49,000. Lazard Asset Management LLC bought a new position in CTI BioPharma in the 3rd quarter worth about $57,000. Finally, Simplicity Solutions LLC bought a new position in CTI BioPharma in the 1st quarter worth about $43,000. Institutional investors own 99.40% of the company’s stock.
CTI BioPharma Company Profile
CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis.
- Get a free copy of the StockNews.com research report on CTI BioPharma (CTIC)
- FREYR Battery Is An Interesting Play On EVs: At Rock Bottom
- Analysts Upgrade GXO Logistics, Its First Quarter Says It All
- The Bottom Is In For AppLovin; Reversal Is Next
- Exact Sciences Serves Investors Exactly What They Wished For
- Shockwave Medical, Fast Grower, In Boston Scientific’s Sights?
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.